ArticleNature2022
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 785 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
785citing papers in PubMed, 3 pooled it
71.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
785 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,178 citations in OpenAlex.
- The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials.BMC infectious diseases · 2026Pooled it
- Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.Influenza and other respiratory viruses · 2023Pooled it
- Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis.World journal of pediatrics : WJP · 2023Pooled it
- Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.Frontiers in public health · 2025Trial
- Trial
- Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Nature communications · 2024Trial
- Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses.PLoS biology · 2026Article
- Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.Journal of virology · 2026Article
- An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models.Viruses · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines.Vaccines · 2026Review
- Fluorinated carbohydrate-based vaccines.Chemical science · 2026Review
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Hybrid immunity following SARS-CoV-2 infection and vaccination is associated with more sustained antibody levels, and lower reinfection risk.Scientific reports · 2026Article
- Article
- Machine learning-guided rational engineering of ACE2-derived peptides for broad-spectrum neutralization of SARS-CoV-2 variants.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors.JCI insight · 2026Article
- Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort.iScience · 2026Article
- Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.Communications medicine · 2026Article
725 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
- Update of
Authors and funding
34 authors at 14 institutions in 6 countries.
Sandile CeleAfrica Health Research Institute, Durban, South Africa.
Laurelle JacksonAfrica Health Research Institute, Durban, South Africa.
David S KhouryKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Khadija KhanAfrica Health Research Institute, Durban, South Africa.
Thandeka Moyo-GweteNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Houriiyah TegallyKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
James Emmanuel SanKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Deborah CromerKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Cathrine ScheepersNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Daniel G AmoakoSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Farina KarimAfrica Health Research Institute, Durban, South Africa.
Mallory BernsteinAfrica Health Research Institute, Durban, South Africa.
Gila LustigCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Muneerah SmithDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-1516-3270
Yashica GangaAfrica Health Research Institute, Durban, South Africa.
Zesuliwe JuleAfrica Health Research Institute, Durban, South Africa.
Kajal ReedoyAfrica Health Research Institute, Durban, South Africa.
Shi-Hsia HwaAfrica Health Research Institute, Durban, South Africa.ORCID http://orcid.org/0000-0002-5648-9808
Jennifer GiandhariKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Jonathan M BlackburnDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-8988-9595
Bernadett I GosnellDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0002-6336-7489
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Willem HanekomAfrica Health Research Institute, Durban, South Africa.
NGS-SA
COMMIT-KZN Team
Anne von GottbergNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Jinal N BhimanNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-6354-4003
Richard J LessellsKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Mahomed-Yunus S MoosaDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Miles P DavenportKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Tulio de OliveiraKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-8719-4028
Alex SigalAfrica Health Research Institute, Durban, South Africa. alex.sigal@ahri.org.ORCID http://orcid.org/0000-0001-8571-2004
Africa Health Research Institute · ZANational Health Laboratory Service · ZACentre for the AIDS Programme of Research in South Africa · ZAUniversity of KwaZulu-Natal · ZAUniversity of Cape Town · ZARagon Institute of MGH, MIT and Harvard · USUniversity of Alabama at Birmingham · USUniversity of Washington · USUNSW Sydney · AUMax Planck Institute for Infection Biology · DEMolecular Diagnostics Services · ZASouth African Association for Marine Biological Research · ZAStellenbosch University · ZAUniversity of Copenhagen · DK
Funding
MURINE MODEL SYSTEM FOR HIV PATHOGENESISR01AI033856 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LITTMAN, DAN · 1993 to 2008
$4.2MIdentification of the HIV Reservoir in Lymph Nodes Using Single Cell RNA-SeqR01AI138546 · NIAID · KWAZULU-NATAL RESEARCH INSTITUTE TB-HIV · PI SIGAL, ALEXANDER · 2018 to 2022
$721kNIAID NIH HHS R01 AI033856NIAID NIH HHS R01 AI138546Wellcome TrustWellcome Trust 221003/Z/20/Z
Abstract
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections
Indexed as
Neutralization TestsAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCell LineChlorocebus aethiopsHumansImmune EvasionMutationSARS-CoV-2Spike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.